Helicobacter pylori is a parasitic bacterium in the stomach that lives between the gastric mucosa and mucus. According to the WHO, more than half of the world's population has H. pylori and is the third leading cause of cancer-related deaths. In 1994, the WHO's IARC classified H. Pylori as a Class 1 carcinogen. The incidence of H. pylori in developing countries is the highest worldwide, highlighting the need for highly accurate and manageable testing. By 2025, the H. pylori testing market is expected to be worth 6 billion. Accordingly, SML Genetree has developed a reagent that can diagnose Helico-bacter pylori and Clarithromycin-resistant mutants (A2142G, A2143G) through DNA extracted from human hygienic tissue using Real-time Polymerase Chain Reaction. Since it contains multiple gene regions, Helico-bacter pylori and Clarithromycin-resistant mutations can be detected sensitively, and high reproducibility has been demonstrated through repeated tests by serially diluting various positive samples and standards. In addition, as a result of clinical evaluation on human sanitary inspection tissue by commissioning a large domestic consignment inspection institution, high sensitivity and specificity were confirmed, proving its excellent clinical performance.
